Laparoscopic colorectal cancer surgery.

abstract：:Anemia is a frequent problem in cancer patients, especially in those treated with chemotherapy, and has an important negative impact on quality of life. Red blood cell transfusions provide clear but rather temporary comfort. The development of erythropoietic stimulating agents (ESAs) led to a more durable anemia treat...

journal_title：Expert review of anticancer therapy

authors： Vansteenkiste J,Wauters I

更新日期：2007-10-01 00:00:00

abstract：:There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglo...

journal_title：Expert review of anticancer therapy

authors： Bazargan A,Tam CS,Keating MJ

更新日期：2012-03-01 00:00:00

abstract：:Breast cancer represents a major health problem, with more than a million new cases and 370,000 deaths worldwide yearly. Options and understanding of how to use cytotoxic chemotherapy in both advanced and early stage breast cancer have made substantial progress in the past 10 years, with numerous landmark studies iden...

journal_title：Expert review of anticancer therapy

authors： Hussain SA,Palmer DH,Stevens A,Spooner D,Poole CJ,Rea DW

更新日期：2005-12-01 00:00:00

abstract：INTRODUCTION:Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast c...

journal_title：Expert review of anticancer therapy

authors： Griguolo G,Dieci MV,Guarneri V,Conte P

更新日期：2018-06-01 00:00:00

abstract：:Systemic chemotherapy provides improvement in both survival and quality of life for patients with advanced non-small-cell lung cancer (NSCLC). Docetaxel is the only agent currently approved for both first- and second-line treatment of advanced NSCLC. Multiple randomized clinical trials have established the efficacy of...

journal_title：Expert review of anticancer therapy

authors： Saloustros E,Georgoulias V

更新日期：2008-08-01 00:00:00

abstract：INTRODUCTION:In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: tempora...

journal_title：Expert review of anticancer therapy

authors： Martínez-Pérez C,Turnbull AK,Dixon JM

更新日期：2019-02-01 00:00:00

abstract：:Introduction: Prodrugs have been used to improve the selectivity and efficacy of cancer therapy by targeting unique abnormal markers that are overexpressed by cancer cells and are absent in normal tissues. In this context, different strategies have been exploited and new ones are being developed each year. Areas cover...

journal_title：Expert review of anticancer therapy

authors： Souza C,Pellosi DS,Tedesco AC

更新日期：2019-06-01 00:00:00

abstract：:Brain tumors are the most common cause of cancer-related death and the second most common form of cancer in pediatric patients. Many of these tumors are treated primarily with surgery, either alone or in combination with radiation or chemotherapy. Recent advances have lead to greater survival and decreased morbidities...

journal_title：Expert review of anticancer therapy

authors： Heuer GG,Jackson EM,Magge SN,Storm PB

更新日期：2007-12-01 00:00:00

abstract：:Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In addition to cytotoxic chemotherapy, treating physicians and their patients now have the option of several new agents that tar...

journal_title：Expert review of anticancer therapy

authors： Shapiro D,Tareen B

更新日期：2012-07-01 00:00:00

abstract：INTRODUCTION:Myelodysplastic syndromes (MDS) represent a range of bone marrow disorders, with patients affected by cytopenias and risk of progression to AML. There are limited therapeutic options available for patients, including hypomethylating agents (azacitidine/decitabine), growth factor support, lenalidomide, and ...

journal_title：Expert review of anticancer therapy

authors： Feld J,Belasen A,Navada SC

更新日期：2020-06-01 00:00:00

abstract：:Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the t...

journal_title：Expert review of anticancer therapy

authors： Kose MF,Meydanli MM,Tulunay G

更新日期：2006-03-01 00:00:00

abstract：:Patients with unilateral breast cancer are at increased risk of developing a second cancer in the contralateral breast. Some women choose contralateral prophylactic mastectomy (CPM) to prevent cancer in the contralateral breast. Several studies have demonstrated that CPM significantly decreases the occurrence of contr...

journal_title：Expert review of anticancer therapy

authors： Tuttle T,Habermann E,Abraham A,Emory T,Virnig B

更新日期：2007-08-01 00:00:00

abstract：INTRODUCTION:Endometrial cancer is a common gynecologic malignancy in the United States, and the recurrence rate depends on the disease stage at diagnosis. Recurrence can affect several areas and follow different patterns. AREAS COVERED:The role of surgery at the time of recurrence is not clearly defined. In this revi...

journal_title：Expert review of anticancer therapy

authors： Zanfagnin V,Ferrero A,Biglia N,Aletti G,Gill SE,Makdisi PB,Multinu F,Mariani A

更新日期：2016-07-01 00:00:00

abstract：:The treatment of renal cell carcinoma is rapidly changing as a result of recent evidence concerning the efficacy of biological drugs, antiangiogenetic agents and signal-transduction inhibitors. This paper will provide a critical overview of the use of immunotherapy in renal cell carcinoma and review the available data...

journal_title：Expert review of anticancer therapy

authors： Passalacqua R,Buti S,Tomasello G,Longarini R,Brighenti M,Dalla Chiesa M

更新日期：2006-10-01 00:00:00

abstract：:Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

journal_title：Expert review of anticancer therapy

authors： Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

更新日期：2010-07-01 00:00:00

abstract：:Whereas radical cystectomy is the standard of care in high-grade, invasive bladder tumors, the extent of lymphadenectomy and its diagnostic and/or therapeutic potential is controversial. Independent predictors for lymph node involvement are T-stage, histological grading and lymphovascular invasion. Preoperative assess...

journal_title：Expert review of anticancer therapy

authors： Nagele U,Anastasiadis AG,Merseburger AS,Sievert KD,Stenzl A,Kuczyk M

更新日期：2006-06-01 00:00:00

abstract：:Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved. Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbocicli...

journal_title：Expert review of anticancer therapy

authors： Onesti CE,Jerusalem G

更新日期：2020-12-13 00:00:00

abstract：:Tamoxifen has been shown to reduce the incidence of estrogen receptor-positive breast cancer by approximately 50% in high-risk women. Similar results are seen for raloxifene, but it has a more favorable side-effect profile. Data on contralateral tumors from women in adjuvant trials treated with aromatase inhibitors su...

journal_title：Expert review of anticancer therapy

authors： Cuzick J

更新日期：2008-09-01 00:00:00

abstract：INTRODUCTION:Fertility impairment due to treatments is a major concern for adolescents and young adult patients who survived cancer. Areas covered: Chemotherapy may determine a detrimental effect on ovary function, leading to infertility, and premature ovarian failure. Embryo and oocyte cryopreservation is a standard s...

journal_title：Expert review of anticancer therapy

authors： Tosoni A,Balestrini D,Brandes AA

更新日期：2017-05-01 00:00:00

abstract：:Introduction: Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour, and its outcome is strongly conditioned by the rapid onset of resistance to conventional chemotherapeutics. First-line treatment with a combination of platinum agents and topoisomerase inhibitors has been the standard of care for...

journal_title：Expert review of anticancer therapy

authors： Van Den Borg R,Leonetti A,Tiseo M,Giovannetti E,Peters GJ

更新日期：2019-06-01 00:00:00

abstract：:Since its first description nearly two centuries ago, melanoma has been a difficult disease to diagnose and treat. With the incidence and mortality rates slowly increasing, understanding this disease is more important than ever. Herein, the current diagnostic and treatment recommendations for melanoma of the head and ...

journal_title：Expert review of anticancer therapy

authors： Lentsch EJ,McMasters KM

更新日期：2003-10-01 00:00:00

abstract：:Positron emission tomography (PET) using [(18)F]-2-deoxy-2-fluoro-d-glucose (FDG) has emerged as a valuable diagnostic modality in patients with non-small cell lung cancer (NSCLC). Data in the literature show that the addition of FDG-PET definitely alters clinical management in patients with potentially resectable NSC...

journal_title：Expert review of anticancer therapy

authors： Oyen WJ,Bussink J,Verhagen AF,Corstens FH,Bootsma GP

更新日期：2004-08-01 00:00:00

abstract：:Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

journal_title：Expert review of anticancer therapy

authors： Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

更新日期：2016-01-01 00:00:00

abstract：:Recurrent non muscle invasive bladder cancer (NMIBC) represents a therapeutic challenge, especially in the case of Bacillus Calmette Guerin (BCG)-failures. Chemohyperthermia (CHT) has been tested as adjuvant therapy in selected categories of patients with promising results. The aim of this systematic review is to expl...

journal_title：Expert review of anticancer therapy

authors： Soria F,Allasia M,Oderda M,Gontero P

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Published data concerning primary mediastinal sarcomas are limited to small-sized retrospective series.  This study reviewed the clinical outcomes of these cases from the SEER (surveillance, epidemiology and end results) database. METHODS:Primary mediastinal sarcomas (1988 - 2013) were assembled from the SE...

journal_title：Expert review of anticancer therapy

authors： Abdel-Rahman O

更新日期：2017-11-01 00:00:00

abstract：:Tyrosine kinase inhibitors have revolutionized the treatment of metastatic renal cell carcinoma (RCC). Drugs such as sorafenib, sunitinib and pazopanib act on the VEGF receptor pathway, but they can also inhibit other kinases, resulting in off-target toxicities. Tivozanib was developed due to its potency and selectivi...

journal_title：Expert review of anticancer therapy

authors： Wong HH,Eisen T

更新日期：2013-06-01 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer deaths with a 5-year survival of 4-6%. Clinical challenges remain to be addressed, since few promising approaches to treat pancreatic cancer have been reported. Here we discuss the potential of a new biotherapeutic agent composed of a lysosomal protein (Saposin C...

journal_title：Expert review of anticancer therapy

authors： Olowokure O,Qi X

更新日期：2014-05-01 00:00:00

abstract：:The characterization of the mantle cell lymphoma (MCL) entity had a major impact on patient management and has played a profound role in improving therapy. Although the prognosis is improving in MCL, there is no definitive proof that the therapies currently available will lead to cure. Few randomized studies have been...

journal_title：Expert review of anticancer therapy

authors： Camara-Clayette V,Hermine O,Ribrag V

更新日期：2012-09-01 00:00:00

abstract：:Lung cancer is a global health issue. Compared with other common malignancies, the prognosis is poor as many patients present with advanced disease. The National Lung Screening Trial (NLST) aimed to identify and treat early lung cancers using annual low-dose computed tomography (CT) screening in a high-risk group. Whe...

journal_title：Expert review of anticancer therapy

authors： Duke SL,Eisen T

更新日期：2011-12-01 00:00:00

abstract：:In clinical practice, approximately 50% of new cases of breast cancer occur in women over the age of 65 years, although very few elderly women have been enrolled in the numerous randomized trials conducted so far. Notwithstanding less aggressive biologic features compared with younger patients, breast cancer impacts o...

journal_title：Expert review of anticancer therapy

authors： Basso U,Brunello A,Pogliani C,Monfardini S

更新日期：2004-04-01 00:00:00